321 related articles for article (PubMed ID: 37947202)
21. Resistance to immune checkpoint inhibitors in advanced lung cancer: Clinical characteristics, potential prognostic factors and next strategy.
Zhou J; Lu X; Zhu H; Ding N; Zhang Y; Xu X; Gao L; Zhou J; Song Y; Hu J
Front Immunol; 2023; 14():1089026. PubMed ID: 36776868
[TBL] [Abstract][Full Text] [Related]
22. An oral cancer vaccine using Bifidobacterium vector augments combination of anti-PD-1 and anti-CTLA-4 antibodies in mouse renal cell carcinoma model.
Ueki H; Kitagawa K; Kato M; Yanase S; Okamura Y; Bando Y; Hara T; Terakawa T; Furukawa J; Nakano Y; Fujisawa M; Shirakawa T
Sci Rep; 2023 Jun; 13(1):9994. PubMed ID: 37340017
[TBL] [Abstract][Full Text] [Related]
23. Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma.
Bersanelli M; Rebuzzi SE; Roviello G; Catalano M; Brunelli M; Rizzo M
Hum Vaccin Immunother; 2023 Dec; 19(1):2171672. PubMed ID: 36758960
[TBL] [Abstract][Full Text] [Related]
24. Tryptophan 2,3-dioxygenase in tumor cells is associated with resistance to immunotherapy in renal cell carcinoma.
Sumitomo M; Takahara K; Zennami K; Nagakawa T; Maeda Y; Shiogama K; Yamamoto Y; Muto Y; Nukaya T; Takenaka M; Fukaya K; Ichino M; Sasaki H; Saito K; Shiroki R
Cancer Sci; 2021 Mar; 112(3):1038-1047. PubMed ID: 33410234
[TBL] [Abstract][Full Text] [Related]
25. The Therapeutic Landscape of Renal Cell Carcinoma: From the Dark Age to the Golden Age.
Huang JJ; Hsieh JJ
Semin Nephrol; 2020 Jan; 40(1):28-41. PubMed ID: 32130964
[TBL] [Abstract][Full Text] [Related]
26. Update on immunotherapy for renal cancer.
Canales Rojas R
Medwave; 2021 Jun; 21(5):e8202. PubMed ID: 34214067
[TBL] [Abstract][Full Text] [Related]
27. Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma.
Carlo MI; Voss MH; Motzer RJ
Nat Rev Urol; 2016 Jul; 13(7):420-31. PubMed ID: 27324121
[TBL] [Abstract][Full Text] [Related]
28. Current Status and Future Directions of Immunotherapy in Renal Cell Carcinoma.
Considine B; Hurwitz ME
Curr Oncol Rep; 2019 Mar; 21(4):34. PubMed ID: 30848378
[TBL] [Abstract][Full Text] [Related]
29. Synergistic effects of the immune checkpoint inhibitor CTLA-4 combined with the growth inhibitor lycorine in a mouse model of renal cell carcinoma.
Li X; Xu P; Wang C; Xu N; Xu A; Xu Y; Sadahira T; Araki M; Wada K; Matsuura E; Watanabe M; Zheng J; Sun P; Huang P; Nasu Y; Liu C
Oncotarget; 2017 Mar; 8(13):21177-21186. PubMed ID: 28416753
[TBL] [Abstract][Full Text] [Related]
30. The impact of antibiotic use on clinical features and survival outcomes of cancer patients treated with immune checkpoint inhibitors.
Zhou J; Huang G; Wong WC; Hu DH; Zhu JW; Li R; Zhou H
Front Immunol; 2022; 13():968729. PubMed ID: 35967438
[TBL] [Abstract][Full Text] [Related]
31. Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.
Xing R; Gao J; Cui Q; Wang Q
Front Immunol; 2021; 12():783236. PubMed ID: 34899747
[TBL] [Abstract][Full Text] [Related]
32. The immunology of renal cell carcinoma.
Díaz-Montero CM; Rini BI; Finke JH
Nat Rev Nephrol; 2020 Dec; 16(12):721-735. PubMed ID: 32733094
[TBL] [Abstract][Full Text] [Related]
33. Current status of antigen-specific T-cell immunotherapy for advanced renal-cell carcinoma.
Xu Y; Miller CP; Warren EH; Tykodi SS
Hum Vaccin Immunother; 2021 Jul; 17(7):1882-1896. PubMed ID: 33667140
[TBL] [Abstract][Full Text] [Related]
34. Immunology and Immunotherapeutic Approaches for Advanced Renal Cell Carcinoma: A Comprehensive Review.
Hah YS; Koo KC
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33923219
[TBL] [Abstract][Full Text] [Related]
35. The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?
Franzin R; Netti GS; Spadaccino F; Porta C; Gesualdo L; Stallone G; Castellano G; Ranieri E
Front Immunol; 2020; 11():574271. PubMed ID: 33162990
[TBL] [Abstract][Full Text] [Related]
36. Novel immunotherapeutic strategies in development for renal cell carcinoma.
Inman BA; Harrison MR; George DJ
Eur Urol; 2013 May; 63(5):881-9. PubMed ID: 23084331
[TBL] [Abstract][Full Text] [Related]
37. Case Report: Successful treatment of late-onset immune checkpoint inhibitor-associated membranous nephropathy in a patient with advanced renal cell carcinoma.
Ratanasrimetha P; Reddy VD; Kala J; Tchakarov A; Glass WF; Msaouel P; Lin JS
Front Immunol; 2022; 13():898811. PubMed ID: 35967405
[TBL] [Abstract][Full Text] [Related]
38. Genomic Profiling and Response to Immune Checkpoint Inhibition plus Tyrosine Kinase Inhibition in FH-Deficient Renal Cell Carcinoma.
Xu Y; Kong W; Cao M; Wang J; Wang Z; Zheng L; Wu X; Cheng R; He W; Yang B; Dong B; Pan J; Chen Y; Huang J; Jiang C; Zhai W; Li F; Chen R; Zhou X; Wu G; Geng X; Chen J; An H; Yuan Y; Xu T; Chen D; Lin D; Xu L; Huang K; Peng L; Yu Y; Tai S; Qi H; Luo K; Kang X; Wang H; Huang Y; Zhang J; Xue W
Eur Urol; 2023 Feb; 83(2):163-172. PubMed ID: 35715365
[TBL] [Abstract][Full Text] [Related]
39. State of the Future: Translational Approaches in Renal Cell Carcinoma in the Immunotherapy Era.
Bakouny Z; Flippot R; Braun DA; Lalani AA; Choueiri TK
Eur Urol Focus; 2020 Jan; 6(1):37-40. PubMed ID: 30827939
[TBL] [Abstract][Full Text] [Related]
40. Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer.
Soria F; Beleni AI; D'Andrea D; Resch I; Gust KM; Gontero P; Shariat SF
World J Urol; 2018 Nov; 36(11):1703-1709. PubMed ID: 29549485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
